Oncotarget

Case Reports:

Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status

Aman Chauhan _, Susanne M. Arnold, Jill Kolesar, Hala Elnakat Thomas, Mark Evers and Lowell Anthony

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:14738-14740. https://doi.org/10.18632/oncotarget.24553

Metrics: PDF 782 views  |   HTML 1548 views  |   ?  


Abstract

Aman Chauhan1, Susanne M. Arnold1, Jill Kolesar1, Hala Elnakat Thomas2, Mark Evers1 and Lowell Anthony1

1Markey Cancer Center, University of Kentucky, Lexington, KY, USA

2University of Cincinnati, Cincinnati, OH, USA

Correspondence to:

Aman Chauhan, email: aman.chauhan@uky.edu

Keywords: large cell neuroendocrine carcinoma; high grade neuroendocrine carcinoma; immune checkpoint inhibitors

Received: December 23, 2017     Accepted: February 13, 2018     Epub: February 22, 2018     Published: March 06, 2018

ABSTRACT

Introduction: Large cell neuroendocrine carcinomas (LCNEC) are a group of rare high grade neuroendocrine tumors that often behave clinically like small cell carcinoma (SCLC) and are treated as such. No major advancement in the management of these tumors has occurred in the last 30 years.

Methods: We present a case series of three cases from Markey Cancer center along with a review of 13 published cases in the literature wherein immune-checkpoint inhibitors were utilized in the management of LCNEC.

Results: Immune-checkpoint inhibitors might have clinical activity in LCNEC.

Conclusion: Role of immune-checkpoint inhibitors should be explored in prospective LCNEC clinical trials. We summarize current evidence regarding use of immune checkpoint inhibitors in the treatment of LCNEC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 24553